Dyne Therapeutics
Gene therapy for inherited muscle diseases
- Sector
- Biotech
- Headquarters
- WALTHAM, MA
- Founded
- 2017
- Latest Form D
- $116M, Aug 2020
- Total capital
- $116M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $116M
- 1 Form D · last Aug 2020
- 74 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 26
- 14 pending · first 2024
- Rank in peer group#26 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$116M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#26 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Catherine Stehman-Breen, M.D.DirectorNamed in SEC Form D filings
- David LubnerDirectorNamed in SEC Form D filings
- Dirk KerstenDirectorNamed in SEC Form D filings
- Edward HurwitzDirectorNamed in SEC Form D filings
- Jason RhodesDirectorNamed in SEC Form D filings
- Jonathan McNeill, M.D.Executive OfficerNamed in SEC Form D filings
Show all 11 people
- Joshua BrummExecutive Officer, DirectorNamed in SEC Form D filings
- Lawrence Klein, Ph.D.DirectorNamed in SEC Form D filings
- Oxana Beskrovnaya, Ph.D.Executive OfficerNamed in SEC Form D filings
- Richard ScalzoExecutive OfficerNamed in SEC Form D filings
- Romesh Subramanian, Ph.D.Executive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 26 granted of 40- New patentMuscle Targeting Complexes And Formulations For Treating Facioscapulohumeral Muscular DystrophyUSPTOUS 12,752,013
- New patentMuscle Targeting Complexes And Uses Thereof For Treating Myotonic DystrophyUSPTOUS 12,746,290
- GrantedMuscle-targeting Complexes And Uses ThereofUSPTOUS 12,742,007
Show all 40 patent records
- Muscle Targeting Complexes And Formulations For Treating Facioscapulohumeral Muscular DystrophyOct 6, 2026 · US 12,752,013Granted
- Muscle Targeting Complexes And Uses Thereof For Treating Myotonic DystrophySep 29, 2026 · US 12,746,290Granted
- Muscle-targeting Complexes And Uses ThereofSep 22, 2026 · US 12,742,007Granted
- Muscle Targeting Complexes And Formulations For Treating DystrophinopathiesAug 27, 2026 · Application 18577348Pending
- Method Of Producing Muscle Targeting Complexes Comprising An Anti-transferrin Receptor Antibody Linked To An OligonucleotideAug 6, 2026 · Application 19378460Pending
- Muscle Targeting Complexes And Formulations For Treating Myotonic DystrophyAug 4, 2026 · US 12,697,394Granted
- Muscle Targeting Complexes And Uses Thereof For Skipping Exon 45 Of A Dmd GeneJul 2, 2026 · Application 19125492Pending
- Complexes Comprising An Anti-Transferrin Receptor Antibody Linked To An Oligonucleotide And Method Of Delivering Oligonucleotide To A SubjectJun 23, 2026 · US 12,662,545Granted
- Muscle Targeting Complexes For Treating DystrophinopathiesMay 21, 2026 · Application 18706057Pending
- Muscle Targeting Complexes And Uses Thereof For Treating DystrophinopathiesMay 19, 2026 · US 12,629,426Granted
- Anti-transferrin Receptor (tfr) Antibody And Uses ThereofMay 12, 2026 · US 12,624,120Granted
- Muscle Targeting Complexes And Formulations For Treating Myotonic DystrophyMar 12, 2026 · Application 19306199Pending
- Muscle Targeting Complexes And Formulations For Treating Facioscapulohumeral Muscular DystrophyFeb 26, 2026 · Application 19382888Pending
- Muscle Targeting Complexes And Uses Thereof For Treating Myotonic DystrophyDec 16, 2025 · US 12,496,352Granted
- Muscle Targeting Complexes And Formulations For Treating Myotonic DystrophyDec 4, 2025 · Application 19306247Pending
- Muscle Targeting Complexes Comprising An Anti-transferrin Receptor Antibody Linked To An Oligonucleotide And Method Of Use Thereof To Treat Duchenne Muscular DystrophyNov 25, 2025 · US 12,478,687Granted
- Muscle Targeting Complexes And Formulations For Treating Myotonic DystrophyNov 6, 2025 · Application 18856264Pending
- Complexes Comprising An Anti-transferrin Receptor Antibody Linked To An Oligonucleotide And Method Of Delivering An Oligonucleotide To A SubjectNov 4, 2025 · US 12,460,011Granted
- Muscle Targeting Complexes And Formulations For Treating Myotonic DystrophyOct 14, 2025 · US 12,440,574Granted
- Muscle Targeting Complexes And Uses Thereof For Treating DystrophinopathiesOct 14, 2025 · US 12,440,575Granted
- Complexes Comprising An Anti-transferrin Receptor Antibody Linked To An Oligonucleotide And Method Of Delivering Oligonucleotide To A SubjectSep 30, 2025 · US 12,428,487Granted
- Muscle Targeting Complexes And Uses Thereof For Treating DystrophinopathiesSep 2, 2025 · US 12,403,203Granted
- Muscle Targeting Complexes And Uses Thereof For Treating Facioscapulohumeral Muscular DystrophyAug 28, 2025 · Application 19188423Pending
- Muscle Targeting Complexes And Uses Thereof For Treating DystrophinopathiesAug 26, 2025 · US 12,397,062Granted
- Dosing Of Muscle Targeting Complexes For Treating Myotonic DystrophyAug 7, 2025 · Application 18856266Pending
- Muscle Targeting Complexes And Uses Thereof For Treating Myotonic DystrophyAug 7, 2025 · Application 18856247Pending
- Complexes Comprising An Anti-transferrin Receptor Antibody Linked to An Oligonucleotide And Method Of Delivering Oligonucleotide To A SubjectJul 29, 2025 · US 12,370,264Granted
- Muscle-targeting Complexes Comprising An Anti-transferin Receptor Antibody Linked To An Oligonucleotide And Method Of Use Thereof To Induce Exon SkippingJul 15, 2025 · US 12,357,703Granted
- Muscle Targeting Complexes And Uses Thereof For Treating DystrophinopathiesJun 17, 2025 · US 12,329,824Granted
- Muscle Targeting Complexes Comprising An Anti-transferrin Receptor Antibody Linked To An Oligonucleotide And Method Of Use Thereof To Induce Exon Skipping Of Exon 44 Of Dystrophin In A SubjectJun 17, 2025 · US 12,329,825Granted
- Method Of Using An Anti-transferrin Receptor Antibody To Deliver An Oligonucleotide To A Subject Having Facioscapulohumeral Muscular DystrophyJun 10, 2025 · US 12,325,753Granted
- Complexes Comprising An Anti-transferrin Receptor Antibody Linked To An Oligonucleotide And Method Of Delivering Oligonucleotide To A SubjectJun 3, 2025 · US 12,319,743Granted
- Muscle Targeting Complexes And Uses Thereof For Treating Myotonic DystrophyApr 22, 2025 · US 12,280,122Granted
- Muscle-targeting Complexes Comprising An Anti-transferrin Receptor Antibody Linked To An Oligonucleotide And Methods Of Use Thereof To Target Dystrophin And To Treat Duchenne Muscular DystrophyApr 1, 2025 · US 12,263,225Granted
- Muscle Targeting Complexes And Uses Thereof For Treating DystrophinopathiesMar 4, 2025 · US 12,239,716Granted
- Muscle Targeting Complexes And Uses Thereof For Treating DystrophinopathiesMar 4, 2025 · US 12,239,717Granted
- Muscle Targeting Complexes And Formulations For Treating DystrophinopathiesFeb 20, 2025 · Application 18896790Pending
- Muscle Targeting Complexes For Treating Facioscapulohumeral Muscular DystrophyJan 23, 2025 · Application 18708815Pending
- Dosing Of Muscle Targeting Complexes For Treating DystrophinopathiesJan 16, 2025 · Application 18692415Pending
- Muscle-targeting Complexes Comprising An Anti-transferrin Receptor Antibody Linked To An OligonucleotideDec 24, 2024 · US 12,173,079Granted
Related companies, and why
- Antares TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Caldera TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Ethyreal BioSimilar federal contract value in Biotech · null in contracts
- Kailera TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Intellia TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Judo BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .